Pharmaceutical sponsor
Boehringer Ingelheim Clinical Trials
Studies where Boehringer Ingelheim is the lead sponsor: its pipeline by phase, what is enrolling now and where. Studies it supports as a collaborator are in the search.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 56Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves…
- Trial name
- NCT07472517
- Testing
- obrixtamig, atezolizumab, carboplatin
- Where
- 245 sites in United States, Argentina and 40 more
- Volunteers
- 670 people
- Sponsor
- Boehringer Ingelheim
Solid Tumours
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
This is a study for people with advanced cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study.
- Trial name
- NCT06581432
- Testing
- Zongertinib
- Where
- 92 sites in United States, Australia and 14 more
- Volunteers
- 588 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study to Test How Much BI 3034701 Gets Into the Blood in Healthy People When Given in Two Different Ways
The aim of the trial is to investigate relative bioavailability of BI 3034701 treatment T vs. BI 3034701 treatment R.
- Trial name
- NCT07837648
- Testing
- BI3034701 formulation II, BI3034701 formulation C1
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Macular Edema
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
This study is open to adults 18 and older with an eye condition called diabetic macular edema. People are required to have a specific type of diabetic macular edema called centre-involved diabetic macular edema (CI-DME) to take…
- Trial name
- NCT06962839
- Testing
- BI 1815368
- Where
- 97 sites in United States, China and 7 more
- Volunteers
- 300 people
- Sponsor
- Boehringer Ingelheim
Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
This study is for adults aged 18 years and older who have a type of fatty liver disease called metabolic dysfunction-associated steatotic liver disease (MASLD).
- Trial name
- NCT07850063
- Testing
- Survodutide
- Where
- 25 sites in United States, China and 3 more
- Volunteers
- 600 people
- Sponsor
- Boehringer Ingelheim
Non-small Cell Lung Cancer
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer…
- Trial name
- NCT07195695
- Testing
- Zongertinib, Pembrolizumab, Atezolizumab
- Where
- 202 sites in United States, Argentina and 26 more
- Volunteers
- 400 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy People to Compare How 2 Different Formulations of Vicadrostat / Empagliflozin Tablets Are Taken up in the Body
The main objective of this trial is to establish the bioequivalence of two different formulations of vicadrostat / empagliflozin in healthy male and female trial participants following oral administration.
- Trial name
- NCT07845630
- Testing
- Vicadrostat, Empagliflozin, Vicadrostat + empagliflozin
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetic Retinopathy
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join the study.
- Trial name
- NCT06321302
- Testing
- BI 764524, Aflibercept (Eylea®) - US only
- Where
- 90 sites in United States, Germany and 7 more
- Volunteers
- 175 people
- Sponsor
- Boehringer Ingelheim
Small Cell Lung Carcinoma (SCLC), Neuroendocrine Neoplasms
A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer
This study is open to adults with small cell lung cancer and other neuroendocrine cancers. The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists.
- Trial name
- NCT05963867
- Testing
- BI 764532, [89Zr]Zr-BI 764532
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Boehringer Ingelheim
Diabetic Macular Edema
A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated
This study is open to adults with diabetic macular edema that involves the center of the eye. The purpose of this study is to find out how well different doses of a medicine called BI 3812465 are tolerated by people with this…
- Trial name
- NCT07553429
- Testing
- Low dose BI 3812465, Medium dose BI 3812465, High dose BI 3812465
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 49 people
- Sponsor
- Boehringer Ingelheim
Completed, with results posted
All 1,017Pancreatic Neoplasms, Solid Tumors
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
This study is open to adults with advanced cancer in the biliary tract, pancreas, lung, or bladder. This is a study for people for whom previous treatment was not successful or no treatment exists.
- Conditions
- Pancreatic Neoplasms, Solid Tumors, Biliary Tract Cancer, Lung Neoplasms
- Trial name
- NCT05512377
- Testing
- Brigimadlin
- Where
- 60 sites in United States, Australia and 14 more
- Volunteers
- 99 people
- Sponsor
- Boehringer Ingelheim
Healthy
Relative Bioavailability of a Single Oral Dose of BI 425809 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects
To investigate whether and to what extent co-administration of multiple doses of itraconazole affect single dose pharmacokinetics of BI 425809 in healthy male subjects
- Trial name
- NCT02342717
- Testing
- BI 425809, Itraconazole
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Depressive Disorder, Major
A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication
This study is open to adults between 18 and 65 years of age who have depression (major depressive disorder). People with a current depressive episode lasting between 2 months and one and a half years can join the study.
- Trial name
- NCT04937829
- Testing
- 5 mg BI 1569912, 20 mg BI 1569912
- Where
- 10 sites in United States
- Volunteers
- 59 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men to Test Whether Food Influences the Amount of BI 3731579 in the Blood
This trial investigates whether food influences the amount of BI 3731579 in the blood.
- Trial name
- NCT06861829
- Testing
- BI 3731579
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men to Test How Well Different Doses of BI 3731579 Are Tolerated
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 3731579 in healthy male subjects.
- Trial name
- NCT06429137
- Testing
- BI 3731579
- Where
- Germany
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim